Clearer Skies Emerge for Private Equity Amidst Challenges: Cherry Bekaert Releases 2023 Private Equity Year-in-Review and 2024 Outlook
RALEIGH, N.C., Feb. 5, 2024 /PRNewswire/ -- Cherry Bekaert (the Firm) has published its annual year-end Private Equity Industry Report outlining important developments that impacted the private investment markets in 2023. The report found many headwinds that slowed private equity dealmaking in 2022 continued to impact the industry over the course of last year, causing deal activity to decline sharply for the second year in a row. The M&A environment is now grappling with its longest decline in over a decade.
Cherry Bekaert's 2023 Private Equity Year-in-Review report looks at challenges, trends & an optimistic outlook for 2024.
The report highlights the many challenges faced by the sector over the last 12 months and features data provided by PitchbookTM and other sources, including proprietary Firm data. Though many of the challenges were carryovers from the previous year (persistent high interest rates and inflation; a stark valuation gap between buyers and sellers; and general market upheavals), other emerging issues dampened deal activity. Nevertheless, private equity as an asset class continued to show its resiliency as sophisticated dealmakers deployed innovative strategies to keep transaction activity on par with historic pre-pandemic averages. Other key findings from the report include:
For the second consecutive year, deal activity trended downward. Sharp decline in deal volume and contracting valuation multiples highlighted challenges across the M&A landscape.
Deal makers came to grips with the higher-for-longer interest rate environment. The fallout from early 2023 bank collapses created longer term liquidity concerns and increased capital costs for private investment funds.
Increased regulatory activity created uncertainty for both LPs and GPs alike. Between SEC rulings and ESG mandates, fund managers and investors are facing increased scrutiny from regulators.
A few bright spots and pockets of opportunity created optimism. The proliferation of carve-out and add-on deals acted as a shock absorber for middle-market deal activity and helped to keep the deal market moving in the face of significant challenges.
Private credit advanced their market share of M&A loan funding. With traditional lender sources reducing debt funding, direct lending helped fill financing gaps caused by the pullback in syndicated debt financings.
Middle market showed resiliency and overperformed other segments. While the middle market was not totally immune from deal stagnation, the sector's decline was less acute compared to the broader M&A market.
Technology and professional services sectors were focus areas of private equity. Technology, particularly with AI as a growing segment, accounted for nearly one-third of leveraged buyout activity, while professional services garnered increasing interest from private equity investors, particularly in categories such as CPA, wealth management and consulting firms.
"While private equity deal activity was sharply down from its pandemic peak, investors opportunistically deployed capital across a range of verticals, asset classes and transaction types to keep the deal market flowing," said Scott Moss, Managing Partner, Private Equity and Transaction Advisory Services. "This further demonstrates the industry's maturity, resilience and general market acuity."
Looking ahead, as markets begin to anticipate interest rate reductions and recession fears continue to dissipate, there is cautious optimism that 2024 may post upward advancements in deal activity.
Cherry Bekaert, ranked among the largest assurance, tax and advisory firms in the U.S., serves clients across industries in all 50 U.S. states and internationally. "Cherry Bekaert" is the brand name under which Cherry Bekaert LLP and Cherry Bekaert Advisory LLC, independently owned entities, provide professional services in an alternative practice structure in accordance with applicable professional standards. Cherry Bekaert LLP is a licensed CPA firm that provides attest services, and Cherry Bekaert Advisory LLC and its subsidiary entities provide business advisory and non-attest services spanning the areas of transaction advisory, risk and accounting advisory, digital solutions, cybersecurity and tax. We exercise a deliberate curiosity to know our clients' industries and work collaboratively to create shared success. For more details, visit cbh.com/disclosure.
Cherry Bekaert LLP and Cherry Bekaert Advisory LLC are members of Allinial Global, an accountancy and business advisory global association. Visit us at cbh.com and follow us on LinkedIn, Facebook,X@CherryBekaert or Instagram.
DiaMedica Therapeutics Inc. , a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its first quarter 2024 financial results will be...
Schneider National, Inc. , a leading transportation and logistics services company, today announced results for the three months ended March 31, 2024.
"The enterprise continued to feel the pressures of the ongoing freight recession in the first...
Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") will report its first quarter 2024 financial results on Thursday, May 9, 2024. Amylyx' senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the...
Today, Marathon Watch and the Jeep® Brand proudly announced the launch of the new Jeep® x Marathon collection ? introducing four feature timepieces that honor each brand's rich history and honorable service supplying the Allied Forces dating back to...
Opta Group LP ("Opta"), a portfolio company of Speyside Equity Advisers ("Speyside"), announces the acquisition of Performix Metallurgical Additives, LLC ("Performix") effective April 1, 2024....
Deep 6 AI, the leader in AI-powered patient recruitment and real-world data (RWD), together with Magnolia Market Access, a provider of tailored RWD insights and strategies for market access, health economics and outcomes research (HEOR), and...